Aspen Pharmacare Holdings Future Growth
Future criteria checks 4/6
Aspen Pharmacare Holdings is forecast to grow earnings and revenue by 21.9% and 7.4% per annum respectively. EPS is expected to grow by 20.8% per annum. Return on equity is forecast to be 9.6% in 3 years.
Key information
21.9%
Earnings growth rate
20.8%
EPS growth rate
| Pharmaceuticals earnings growth | 19.7% |
| Revenue growth rate | 7.4% |
| Future return on equity | 9.6% |
| Analyst coverage | Low |
| Last updated | 13 Dec 2024 |
Recent future growth updates
Recent updates
We Think Shareholders May Want To Consider A Review Of Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Package
Nov 29
Aspen Pharmacare Holdings Limited (JSE:APN) Not Lagging Market On Growth Or Pricing
Nov 09Aspen Pharmacare Holdings' (JSE:APN) Conservative Accounting Might Explain Soft Earnings
Oct 10Here's Why Aspen Pharmacare Holdings (JSE:APN) Has A Meaningful Debt Burden
Oct 01Aspen Pharmacare Holdings (JSE:APN) Has Announced That It Will Be Increasing Its Dividend To ZAR3.59
Sep 10We Think Aspen Pharmacare Holdings (JSE:APN) Can Stay On Top Of Its Debt
May 08Aspen Pharmacare Holdings Limited's (JSE:APN) P/E Still Appears To Be Reasonable
Mar 05Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Dec 22Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation Is Looking A Bit Stretched At The Moment
Dec 01Aspen Pharmacare Holdings (JSE:APN) Has A Pretty Healthy Balance Sheet
Mar 31With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Makes An Interesting Case
Jan 11These 4 Measures Indicate That Aspen Pharmacare Holdings (JSE:APN) Is Using Debt Reasonably Well
Oct 22We Ran A Stock Scan For Earnings Growth And Aspen Pharmacare Holdings (JSE:APN) Passed With Ease
Oct 06Aspen Pharmacare Holdings' (JSE:APN) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21Aspen Pharmacare Holdings Limited (JSE:APN) Analysts Just Cut Their EPS Forecasts Substantially
Sep 08Aspen Pharmacare Holdings (JSE:APN) Is Increasing Its Dividend To ZAR3.26
Sep 07Here's Why We Think Aspen Pharmacare Holdings (JSE:APN) Might Deserve Your Attention Today
Jun 15Aspen Pharmacare Holdings (JSE:APN) Seems To Use Debt Quite Sensibly
Apr 02With EPS Growth And More, Aspen Pharmacare Holdings (JSE:APN) Is Interesting
Mar 16An Intrinsic Calculation For Aspen Pharmacare Holdings Limited (JSE:APN) Suggests It's 33% Undervalued
Mar 02Is Aspen Pharmacare Holdings (JSE:APN) A Risky Investment?
Dec 23Shareholders Will Probably Not Have Any Issues With Aspen Pharmacare Holdings Limited's (JSE:APN) CEO Compensation
Dec 02We Think Aspen Pharmacare Holdings' (JSE:APN) Robust Earnings Are Conservative
Oct 11After Leaping 42% Aspen Pharmacare Holdings Limited (JSE:APN) Shares Are Not Flying Under The Radar
Sep 30Aspen Pharmacare Holdings Limited (JSE:APN) Looks Just Right With A 42% Price Jump
Sep 30Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2027 | 55,579 | 9,107 | 6,799 | 12,732 | 5 |
| 6/30/2026 | 52,192 | 8,059 | 6,246 | 11,503 | 5 |
| 6/30/2025 | 47,880 | 6,715 | 4,730 | 9,851 | 5 |
| 6/30/2024 | 44,706 | 4,404 | 692 | 6,225 | N/A |
| 3/31/2024 | 43,703 | 4,636 | 1,023 | 6,248 | N/A |
| 12/31/2023 | 42,700 | 4,868 | 1,354 | 6,271 | N/A |
| 9/30/2023 | 41,705 | 5,048 | 1,849 | 5,896 | N/A |
| 6/30/2023 | 40,709 | 5,228 | 2,343 | 5,520 | N/A |
| 3/31/2023 | 39,542 | 5,515 | 2,545 | 5,420 | N/A |
| 12/31/2022 | 38,375 | 5,802 | 2,747 | 5,320 | N/A |
| 9/30/2022 | 38,491 | 6,145 | 2,875 | 5,347 | N/A |
| 6/30/2022 | 38,606 | 6,488 | 3,002 | 5,374 | N/A |
| 3/31/2022 | 38,560 | 6,185 | 3,826 | 6,110 | N/A |
| 12/31/2021 | 38,514 | 5,881 | 4,649 | 6,846 | N/A |
| 9/30/2021 | 38,140 | 5,340 | 4,209 | 6,836 | N/A |
| 6/30/2021 | 37,766 | 4,798 | 3,769 | 6,825 | N/A |
| 3/31/2021 | 35,760 | 3,954 | 4,119 | 7,115 | N/A |
| 12/31/2020 | 36,308 | 3,782 | 4,468 | 7,405 | N/A |
| 9/30/2020 | 34,984 | 3,581 | 5,141 | 7,833 | N/A |
| 6/30/2020 | 33,659 | 3,380 | 5,814 | 8,260 | N/A |
| 3/31/2020 | 39,927 | 3,272 | 4,508 | 7,573 | N/A |
| 12/31/2019 | 33,620 | 870 | 3,202 | 6,886 | N/A |
| 9/30/2019 | 34,567 | 1,275 | 2,856 | 6,444 | N/A |
| 6/30/2019 | 35,514 | 1,679 | 2,509 | 6,002 | N/A |
| 3/31/2019 | 36,880 | 3,350 | 1,400 | 5,864 | N/A |
| 12/31/2018 | 36,683 | 4,890 | 291 | 5,726 | N/A |
| 9/30/2018 | 37,499 | 5,256 | -429 | 6,372 | N/A |
| 6/30/2018 | 38,314 | 5,621 | -1,149 | 7,017 | N/A |
| 3/31/2018 | 39,618 | 5,682 | N/A | 6,653 | N/A |
| 12/31/2017 | 40,922 | 5,743 | N/A | 6,289 | N/A |
| 9/30/2017 | 41,068 | 5,436 | N/A | 6,388 | N/A |
| 6/30/2017 | 41,213 | 5,128 | N/A | 6,487 | N/A |
| 3/31/2017 | 39,557 | 4,414 | N/A | 5,694 | N/A |
| 12/31/2016 | 37,900 | 3,700 | N/A | 4,900 | N/A |
| 9/30/2016 | 36,750 | 4,000 | N/A | 4,050 | N/A |
| 6/30/2016 | 35,600 | 4,300 | N/A | 3,200 | N/A |
| 3/31/2016 | 35,583 | 5,220 | N/A | 3,406 | N/A |
| 12/31/2015 | 35,567 | 6,140 | N/A | 3,613 | N/A |
| 9/30/2015 | 35,833 | 5,670 | N/A | 4,206 | N/A |
| 6/30/2015 | 36,100 | 5,200 | N/A | 4,800 | N/A |
| 3/31/2015 | 35,836 | 5,369 | N/A | 5,074 | N/A |
| 12/31/2014 | 35,572 | 5,537 | N/A | 5,347 | N/A |
| 9/30/2014 | 32,544 | 5,272 | N/A | 4,592 | N/A |
| 6/30/2014 | 29,515 | 5,008 | N/A | 3,836 | N/A |
| 3/31/2014 | 25,901 | 4,388 | N/A | 3,841 | N/A |
| 12/31/2013 | 22,287 | 3,768 | N/A | 3,847 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: APN's forecast earnings growth (21.9% per year) is above the savings rate (9.7%).
Earnings vs Market: APN's earnings (21.9% per year) are forecast to grow faster than the ZA market (19% per year).
High Growth Earnings: APN's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: APN's revenue (7.4% per year) is forecast to grow faster than the ZA market (3.8% per year).
High Growth Revenue: APN's revenue (7.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: APN's Return on Equity is forecast to be low in 3 years time (9.6%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:22 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Aspen Pharmacare Holdings Limited is covered by 18 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andre Bekker | Arqaam Capital Research Offshore S.A.L. |
| Boitshepo Seruwe | Avior Capital Markets |
| Simon Mather | Barclays |